CGL
EW icon

Clarius Group LLC’s Edwards Lifesciences EW Stock Holding History

Clarius Group LLC’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$222K Sell
2,602
-78
-3% -$6.4K 0.01% 355
2025
Q3 		$208K Sell
2,680
-1,913
-42% -$149K 0.01% 376
2025
Q2 		$359K Sell
4,593
-176
-4% -$13.1K 0.02% 312
2025
Q1 		$346K Sell
4,769
-78
-2% -$5.58K 0.02% 311
2024
Q4 		$359K Buy
4,847
+404
+9% +$28.3K 0.02% 272
2024
Q3 		$295K Sell
4,443
-108
-2% -$7.85K 0.02% 321
2024
Q2 		$420K Sell
4,551
-111
-2% -$9.83K 0.03% 242
2024
Q1 		$446K Sell
4,662
-657
-12% -$55.2K 0.03% 246
2023
Q4 		$406K Sell
5,319
-1,248
-19% -$86.8K 0.03% 280
2023
Q3 		$455K Sell
6,567
-2,003
-23% -$161K 0.04% 239
2023
Q2 		$808K Buy
8,570
+389
+5% +$33.8K 0.06% 170
2023
Q1 		$677K Buy
8,181
+198
+2% +$15.6K 0.06% 189
2022
Q4 		$596K Sell
7,983
-66
-0.8% -$5.09K 0.05% 212
2022
Q3 		$665K Sell
8,049
-59
-0.7% -$5.68K 0.07% 171
2022
Q2 		$771K Buy
8,108
+1,134
+16% +$117K 0.08% 153
2022
Q1 		$903K Hold
6,974
– – 0.07% 151
2021
Q4 		$903K Buy
6,974
+59
+0.9% +$6.88K 0.07% 151
2021
Q3 		$783K Buy
6,915
+258
+4% +$29.4K 0.07% 152
2021
Q2 		$689K Buy
6,657
+91
+1% +$8.58K 0.06% 162
2021
Q1 		$549K Buy
6,566
+348
+6% +$29.4K 0.05% 174
2020
Q4 		$567K Buy
6,218
+1,228
+25% +$102K 0.06% 157
2020
Q3 		$398K Buy
4,990
+322
+7% +$25.1K 0.05% 173
2020
Q2 		$323K Buy
4,668
+255
+6% +$18.1K 0.05% 206
2020
Q1 		$277K Sell
4,413
-204
-4% -$14.7K 0.05% 189
2019
Q4 		$364K Sell
4,617
-204
-4% -$15.9K 0.06% 169
2019
Q3 		$353K Buy
4,821
+780
+19% +$54.8K 0.06% 162
2019
Q2 		$249K Buy
4,041
+588
+17% +$35.6K 0.05% 202
2019
Q1 		$220K Buy
+3,453
New +$197K 0.05% 186

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Clarius Group LLC's EW Position: Q4 2025 in Review

Clarius Group LLC reduced its Edwards Lifesciences (EW) stake by 2.9% in Q4 2025, selling an estimated $6.4K and leaving 2,602 shares worth $222K. The position accounts for 0.01% of the portfolio, ranked #355.

Clarius Group LLC first reported a position in EW in Q1 2019 and has held it in 28 quarters since. The position peaked at $903K in Q1 2022. 1,314 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Clarius Group LLC held 2,602 shares of Edwards Lifesciences worth $222K as of Q4 2025.
  • Clarius Group LLC sold 78 Edwards Lifesciences shares in Q4 2025, an estimated $6.4K.
  • Edwards Lifesciences made up 0.01% of Clarius Group LLC's portfolio in Q4 2025, its #355 holding.
  • Clarius Group LLC first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 28 quarters since.
  • Clarius Group LLC's Edwards Lifesciences position peaked at $903K in Q1 2022.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.